In 2018, Silvano has become a Venture Partner at Sofinnova.
Silvano is the founder and Chairman of the board of BiovelocITA, Italy’s first biotech accelerator, sponsored by Sofinnova. He founded EOS S.p.A. (Ethical Oncology Science), a Sofinnova Capital V portfolio company, in 2006 and has been its Chairman and CEO until the company was acquired by Clovis Oncology, Inc in 2013 for up to $470m.
Previously Silvano was co-founder and CEO of Novuspharma, a Sofinnova Capital III portfolio company. In 2000, the company went public on the Italian Nuovo Mercato, raising more than €160m. Novuspharma was acquired by Cell Therapeutics, Inc. (CTI) in 2003.
Silvano was previously Head of R&D at Boehringer Mannheim Italy. He holds a degree in Organic Chemistry achieved at the University of Pisa. Sofinnova has been the lead investor in all these initiatives.